Insider Selling: Pharvaris (NASDAQ:PHVS) Director Sells $298,200.00 in Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Robert Glassman sold 10,000 shares of the stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $29.82, for a total value of $298,200.00. Following the completion of the transaction, the director directly owned 10,500 shares in the company, valued at approximately $313,110. This represents a 48.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

Pharvaris Stock Performance

PHVS stock opened at $30.54 on Friday. Pharvaris N.V. has a fifty-two week low of $15.46 and a fifty-two week high of $33.33. The business’s 50-day moving average is $28.41 and its two-hundred day moving average is $26.79. The company has a market cap of $2.00 billion, a price-to-earnings ratio of -9.60 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last posted its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. Equities analysts predict that Pharvaris N.V. will post -3.25 earnings per share for the current year.

Institutional Trading of Pharvaris

Institutional investors have recently made changes to their positions in the business. Tudor Investment Corp ET AL purchased a new stake in shares of Pharvaris during the third quarter worth about $1,943,000. Patient Square Capital LP grew its position in shares of Pharvaris by 41.4% during the third quarter. Patient Square Capital LP now owns 345,381 shares of the company’s stock worth $8,617,000 after purchasing an additional 101,098 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Pharvaris by 710.4% during the third quarter. JPMorgan Chase & Co. now owns 27,085 shares of the company’s stock worth $676,000 after purchasing an additional 23,743 shares in the last quarter. Integral Health Asset Management LLC purchased a new stake in shares of Pharvaris during the third quarter worth about $4,990,000. Finally, Boothbay Fund Management LLC grew its position in shares of Pharvaris by 735.1% during the third quarter. Boothbay Fund Management LLC now owns 135,181 shares of the company’s stock worth $3,373,000 after purchasing an additional 118,994 shares in the last quarter.

Analyst Ratings Changes

PHVS has been the topic of a number of recent research reports. Wall Street Zen raised Pharvaris from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Citigroup reissued a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Citizens Jmp decreased their price objective on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 13th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Pharvaris in a research note on Tuesday, March 3rd. Finally, Royal Bank Of Canada decreased their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research note on Monday, April 6th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $49.18.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.